Although pharmacological interventions targeting sarcopenia are under investigation, contemporary research indicates that androgen analogues may play a role in male sarcopenic patients by modulating hormone levels to enhance muscle protein synthesis.[18] Additionally, other pharmacological agents aim to ameliorate sarcopenia by modulating signaling pathways associated with muscle metabolism, such as the mTOR pathway; however, no specific drugs have yet achieved widespread clinical application.[19]. The gene discussed is MTOR; the disease is sarcopenia.